Natera Reports Strong Q1 Revenue Growth Despite EPS Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy NTRA?
Source: seekingalpha
Natera's stock fell 5.17% as it crossed below the 5-day SMA, despite positive market conditions with the Nasdaq-100 up 1.00% and S&P 500 up 0.51%.
The company reported a Q1 GAAP EPS of -$0.60, missing expectations by $0.05, but achieved revenue of $696.6 million, reflecting a robust 38.8% year-over-year growth and exceeding market expectations by $79.53 million. Additionally, Natera raised its 2026 annual revenue guidance midpoint by $120 million, indicating strong confidence in future performance.
Despite the earnings miss, the significant revenue growth and raised guidance suggest a solid market position for Natera, particularly in oncology testing, which saw a 54.4% increase in processed tests. This performance may help the company regain investor confidence moving forward.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTRA
Wall Street analysts forecast NTRA stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 194.240
Low
205.00
Averages
262.92
High
300.00
Current: 194.240
Low
205.00
Averages
262.92
High
300.00
About NTRA
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Natera Reports 39% Revenue Growth in Q1 2026
- Significant Revenue Growth: Natera reported $697 million in revenue for Q1 2026, representing a 39% year-over-year increase, highlighting strong performance in women's health and oncology, which further solidifies its market position.
- Surge in Product Orders: The Fetal Focus product is approaching 200,000 orders, marking a successful launch in women's health that is expected to drive future revenue growth and increase market share.
- Clinical Trial Progress: Enrollment in oncology clinical trials is ahead of schedule, with a targeted launch for new products in 2027, prompting management to increase R&D spending by $50 million to accelerate trial timelines, demonstrating confidence in future market opportunities.
- Gross Margin Guidance Raised: Management has raised the gross margin guidance for 2026 to 65%, reflecting an optimistic outlook on revenue growth, despite the rapid increase in volumes in Q1 exerting short-term pressure on margins.
See More
Natera Q1 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Performance: Natera reported a Q1 GAAP EPS of -$0.60, missing expectations by $0.05, yet achieved revenue of $696.6 million, reflecting a robust 38.8% year-over-year growth and exceeding market expectations by $79.53 million, indicating strong market performance.
- Testing Volume Growth: The company processed approximately 1,013,600 tests in Q1 2026, an 18.5% increase from about 855,100 tests in Q1 2025, demonstrating sustained demand for its testing services and enhancing its competitive position in the market.
- Oncology Testing Surge: In oncology, approximately 258,900 tests were processed in Q1 2026, up 54.4% from about 167,700 in Q1 2025, showcasing strong growth momentum in this segment and further solidifying Natera's leadership in oncology testing.
- Revenue Guidance Increase: Natera raised its 2026 annual revenue guidance midpoint by $120 million, adjusting the range from $2.62 billion - $2.70 billion to $2.74 billion - $2.82 billion, reflecting confidence in future performance despite a 1% decline in share price.
See More
Strait of Hormuz Reopening Boosts Healthcare Stocks
- Oil Price Impact on Healthcare Costs: The reopening of the Strait of Hormuz has led to a decrease in global logistics and energy costs, directly reducing operational expenses for healthcare providers and medical device manufacturers, thereby enhancing profit margins and improving quarterly earnings outlooks.
- Risk Appetite Resurgence: The ceasefire has sparked a 'risk-on' sentiment, driving investors back into high-growth biotech and pharmaceutical stocks, which is expected to facilitate funding for long-term R&D and clinical trials that were previously hindered by macroeconomic uncertainties.
- Reduced Market Volatility: As broader market volatility recedes, investor confidence in elective procedures and pharmaceutical demand strengthens, with expectations that this trend will continue through 2026, further stabilizing the global economy.
- Natera's Stock Volatility: Natera's shares have experienced 13 moves greater than 5% in the past year; today's 5.4% increase indicates market recognition of the news's significance, yet the stock remains down 8.9% year-to-date, trading 18.1% below its 52-week high.
See More
Latest Rating Changes on Wall Street
- Infleqtion Coverage Initiation: Citigroup initiates coverage of quantum computing firm Infleqtion with a Buy/High Risk rating and a $20 price target, highlighting its uniqueness in the quantum computing sector, which may attract investor interest.
- SAP Downgrade: Piper Sandler downgrades SAP from Overweight to Neutral, citing challenges in the macroeconomic environment and anticipating lower valuation multiples as the software industry transitions from SaaS to AI.
- Positive Catalysts for Alphabet: Citigroup adds a 90-day Catalyst Watch on Alphabet, expecting upcoming product updates during events like Google Cloud Next and YouTube Brandcast to drive stock price appreciation.
- Biogen Upgrade: Piper Sandler upgrades Biogen from Neutral to Overweight, raising the price target from $177 to $214, reflecting confidence in its growth potential moving forward.
See More
Natera Wins Patent Dispute, Secures 30% Ongoing Royalty
- Patent Validity Upheld: The U.S. District Court for Delaware confirmed the validity of Natera's three asserted MRD patents, ensuring damages related to Invitae's MRD-related products, which further solidifies Natera's innovative strength in this space.
- Ongoing Royalty Arrangement: The court's ruling establishes a 30% ongoing royalty on certain post-injunction sales, a decision that not only protects Natera's revenue stream but also provides a stable financial outlook for future sales.
- Pre-Injunction Revenue Unchanged: The jury maintained an effective royalty of 20.5% on pre-injunction revenues, indicating Natera's strong position in the patent dispute and ensuring the company's competitiveness in the market.
- Patent Portfolio Advantage: With over 650 issued or pending patents, Natera's robust MRD patent portfolio provides a solid foundation for future growth, particularly in the rapidly evolving oncology testing sector.
See More
Natera Wins Patent Litigation Update with 30% Ongoing Royalty
- Court Decision Impact: The U.S. District Court in Delaware ruled on April 6, 2026, that Natera will receive a 30% ongoing royalty on post-injunction revenues from infringing MRD-related product sales, demonstrating strong judicial support for Natera's patents.
- Patent Validity Confirmation: The jury upheld the validity of all three asserted MRD patents, ensuring damages related to Invitae's MRD products, which further solidifies Natera's innovative position in the precision medicine sector.
- Ongoing Revenue Potential: This ruling not only confirms a 30% ongoing royalty on post-injunction revenues but also maintains the effective royalty of 20.5% on pre-injunction revenues, indicating stable revenue growth prospects for Natera.
- Robust Patent Portfolio: Natera boasts over 650 issued or pending patents, particularly strong in the MRD domain, highlighting its leadership in cell-free DNA and precision medicine.
See More
Natera Reports 39% Revenue Growth in Q1 2026
- Significant Revenue Growth: Natera reported $697 million in revenue for Q1 2026, representing a 39% year-over-year increase, highlighting strong performance in women's health and oncology, which further solidifies its market position.
- Surge in Product Orders: The Fetal Focus product is approaching 200,000 orders, marking a successful launch in women's health that is expected to drive future revenue growth and increase market share.
- Clinical Trial Progress: Enrollment in oncology clinical trials is ahead of schedule, with a targeted launch for new products in 2027, prompting management to increase R&D spending by $50 million to accelerate trial timelines, demonstrating confidence in future market opportunities.
- Gross Margin Guidance Raised: Management has raised the gross margin guidance for 2026 to 65%, reflecting an optimistic outlook on revenue growth, despite the rapid increase in volumes in Q1 exerting short-term pressure on margins.
See More
Natera Q1 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Performance: Natera reported a Q1 GAAP EPS of -$0.60, missing expectations by $0.05, yet achieved revenue of $696.6 million, reflecting a robust 38.8% year-over-year growth and exceeding market expectations by $79.53 million, indicating strong market performance.
- Testing Volume Growth: The company processed approximately 1,013,600 tests in Q1 2026, an 18.5% increase from about 855,100 tests in Q1 2025, demonstrating sustained demand for its testing services and enhancing its competitive position in the market.
- Oncology Testing Surge: In oncology, approximately 258,900 tests were processed in Q1 2026, up 54.4% from about 167,700 in Q1 2025, showcasing strong growth momentum in this segment and further solidifying Natera's leadership in oncology testing.
- Revenue Guidance Increase: Natera raised its 2026 annual revenue guidance midpoint by $120 million, adjusting the range from $2.62 billion - $2.70 billion to $2.74 billion - $2.82 billion, reflecting confidence in future performance despite a 1% decline in share price.
See More
Strait of Hormuz Reopening Boosts Healthcare Stocks
- Oil Price Impact on Healthcare Costs: The reopening of the Strait of Hormuz has led to a decrease in global logistics and energy costs, directly reducing operational expenses for healthcare providers and medical device manufacturers, thereby enhancing profit margins and improving quarterly earnings outlooks.
- Risk Appetite Resurgence: The ceasefire has sparked a 'risk-on' sentiment, driving investors back into high-growth biotech and pharmaceutical stocks, which is expected to facilitate funding for long-term R&D and clinical trials that were previously hindered by macroeconomic uncertainties.
- Reduced Market Volatility: As broader market volatility recedes, investor confidence in elective procedures and pharmaceutical demand strengthens, with expectations that this trend will continue through 2026, further stabilizing the global economy.
- Natera's Stock Volatility: Natera's shares have experienced 13 moves greater than 5% in the past year; today's 5.4% increase indicates market recognition of the news's significance, yet the stock remains down 8.9% year-to-date, trading 18.1% below its 52-week high.
See More
Latest Rating Changes on Wall Street
- Infleqtion Coverage Initiation: Citigroup initiates coverage of quantum computing firm Infleqtion with a Buy/High Risk rating and a $20 price target, highlighting its uniqueness in the quantum computing sector, which may attract investor interest.
- SAP Downgrade: Piper Sandler downgrades SAP from Overweight to Neutral, citing challenges in the macroeconomic environment and anticipating lower valuation multiples as the software industry transitions from SaaS to AI.
- Positive Catalysts for Alphabet: Citigroup adds a 90-day Catalyst Watch on Alphabet, expecting upcoming product updates during events like Google Cloud Next and YouTube Brandcast to drive stock price appreciation.
- Biogen Upgrade: Piper Sandler upgrades Biogen from Neutral to Overweight, raising the price target from $177 to $214, reflecting confidence in its growth potential moving forward.
See More
Natera Wins Patent Dispute, Secures 30% Ongoing Royalty
- Patent Validity Upheld: The U.S. District Court for Delaware confirmed the validity of Natera's three asserted MRD patents, ensuring damages related to Invitae's MRD-related products, which further solidifies Natera's innovative strength in this space.
- Ongoing Royalty Arrangement: The court's ruling establishes a 30% ongoing royalty on certain post-injunction sales, a decision that not only protects Natera's revenue stream but also provides a stable financial outlook for future sales.
- Pre-Injunction Revenue Unchanged: The jury maintained an effective royalty of 20.5% on pre-injunction revenues, indicating Natera's strong position in the patent dispute and ensuring the company's competitiveness in the market.
- Patent Portfolio Advantage: With over 650 issued or pending patents, Natera's robust MRD patent portfolio provides a solid foundation for future growth, particularly in the rapidly evolving oncology testing sector.
See More
Natera Wins Patent Litigation Update with 30% Ongoing Royalty
- Court Decision Impact: The U.S. District Court in Delaware ruled on April 6, 2026, that Natera will receive a 30% ongoing royalty on post-injunction revenues from infringing MRD-related product sales, demonstrating strong judicial support for Natera's patents.
- Patent Validity Confirmation: The jury upheld the validity of all three asserted MRD patents, ensuring damages related to Invitae's MRD products, which further solidifies Natera's innovative position in the precision medicine sector.
- Ongoing Revenue Potential: This ruling not only confirms a 30% ongoing royalty on post-injunction revenues but also maintains the effective royalty of 20.5% on pre-injunction revenues, indicating stable revenue growth prospects for Natera.
- Robust Patent Portfolio: Natera boasts over 650 issued or pending patents, particularly strong in the MRD domain, highlighting its leadership in cell-free DNA and precision medicine.
See More
